- Obtained an exclusive license to commercialize Polycaprolactone Microsphere Gelfor Injection and Calcium Hydroxylapatite Microsphere Gel for Injection in Mainland China, Hong Kong, Macao and Taiwan;
- Through regenerative materials’degradation, these two products can stimulate human body’s collagen regeneration and produce a dual effect of “fill and regeneration repairing”. In addition, these two products are suitable for different facial problems respectively, providing personalized solutions for consumers;
- The products will synergize with CMS Skinhealth’smarketed Korean hyaluronic acid product, Vmonalisa, and the pipeline product Poly-L-lactic Acid Microparticle Filler Injection, creating a professional and three-dimensional product matrix and providing comprehensive facial solutions to consumers.
On January 16, 2024, the subsidiary of China Medical System Holdings Limited (“CMS”) – a dermatology and medical aesthetic company “CMS Skinhealth” entered into an exclusive license agreement with Jiangsu Xihong Biopharma Co., Ltd. (“Xihong Biopharma”) for two regenerative medical aesthetic products, Polycaprolactone Microsphere Gel for Injection and Calcium Hydroxylapatite Microsphere Gel for Injection. In accordance with the license agreement, CMS Skinhealth obtained an exclusive license to promote, market and commercialize the above two products in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region and Taiwan. The exclusive license period shall begin from the date of the approval of the registration certificate of Class III medical device of the Product in Mainland China and shall last until the tenth anniversary of the aforementioned date of approval. Upon the expiration of the aforementioned term, the license period may automatically be extended for another period of ten years thereafter if it complies with the exclusive license agreement.
Polycaprolactone Microsphere Gel for Injection and Calcium Hydroxylapatite Microsphere Gel for Injection are injectable implants developed for subcutaneous layer and deep dermis to correct moderate to severe nasolabial fold wrinkles. Two products are Class III medical devices and currently in China’s registrational clinical trials. As regenerative injections, these two products stimulate human body’s collagen regeneration through regenerative materials degradation and produce a dual effect of “fill and regeneration repairing” to achieve long-lasting, natural and safe facial rejuvenation effects. In addition, these two products are suitable for different facial problems respectively, providing personalized solutions for consumers.
Mr. Huang Anjun, the general manager of CMS Skinhealth, stated that CMS Skinhealth established its first cooperation with Xihong Biopharma in May 2023, to obtain the exclusive license of Poly-L-lactic Acid Microparticle Filler Injection. The new cooperation of Polycaprolactone Microsphere Gel for Injection and Calcium Hydroxylapatite Microsphere Gel for Injection will enrich CMS Skinhealth’s regenerative medical aesthetic product portfolio, enhancing the competitiveness of the company. The series of regenerative medical aesthetic products will synergize with existing mainstream light medical aesthetic products such as the marketed Korean hyaluronic acid product, Vmonalisa, creating a professional and three-dimensional facial comprehensive solution, accurately meeting the increasingly diverse and personalized needs of consumers for beauty.
Polycaprolactone Microsphere Gel for Injection
The product is mainly composed of polycaprolactone (PCL) microspheres and gel carrier. PCL is a completely degradable medical material with wide clinical applications. Meanwhile, the less irritating gel carrier makes the product have good biocompatibility, which effectively reduces adverse reactions. Therefore, while achieving rapid filling and shaping, the product stimulates autologous collagen regeneration. In addition, this product contains lidocaine hydrochloride with local anesthetic effect, reducing injection pain and delivering patients a better experience.
Calcium Hydroxylapatite Microsphere Gel for Injection
The product is mainly made of calcium hydroxyphosphate (CaHA) microspheres and gel carrier. CaHA has mature clinical applications and its metabolites are calcium and phosphorus inorganic substances which have similar composition to human bones and can be completely absorbed by human body, ensuring the product’s high biocompatibility and safety. The product uses an improved microsphere processing technique and a scientifically proportioned gel, making the microspheres distributed evenly within the skin tissue, reducing filler displacement and gently stimulating human body’s collagen regeneration, to achieve a long-lasting, natural-looking face slimming effect.
With the increasing demand for anti-aging and the improvement of production technology, the application scenarios of regenerative materials have gradually extended from medical field to medical aesthetic field, enriching the varieties and optimizing the efficacy of light medical aesthetic products. With the development of regenerative materials, light medical aesthetics has entered into the “Regeneration Era” from the “Filling Era”. According to Frost & Sullivan’s forecast, China’s market size for medical aesthetic injectable implants will reach approximately RMB55.8 billion in 2025. As an upgraded category of medical aesthetic injectable implants, regenerative medical aesthetic products have entered a period of rapid growth. CMS Skinhealth will utilize rich resources and channels in dermatology and medical aesthetics fields, seizing the expansion opportunity in the medical aesthetics market, and bring more high-quality and trustworthy professional medical aesthetics products to consumers with pharmaceutical enterprise’s rigorous and professional attitude.
About Xihong Biopharma
Founded in 2016, Xihong Biopharma, is a healthcare company focusing on research and development, production and sales of Class III medical aesthetic devices and formula food for special medical use. The company is dedicated to the technological innovation and upgrading of regenerative medical aesthetic materials, having complete production facilities and mature industrialization landing and industrial-chain operation capability. Please refer to the company’s official website for details: https://www.jsxihong.com/
About CMS Skinhealth
CMS’s Dermatology and Medical Aesthetic Business adheres to an operation philosophy of “using medical thinking to promote in-depth study of dermatology and aesthetics”, and it adopts the scientific mindset to build the dermatology and medical aesthetic product matrix with dermatology prescription products as the core, achieving full life-cycle skin-health management covering dermatological treatment, skincare and medical aesthetics. As of 31 December 2022, team size of CMS Skinhealth exceeded 600 people, covering nearly 10,000 hospitals and medical institutions in China.